Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Supplementation with enteral iron 6 mg/kg/day, compared with the recommended 2-mg/kg/day dose, results in improved iron status and reduced intestinal barrier dysfunction without harming the gut microbiome, according to a study.

High-dose enteral iron improves iron status with no gut microbiome disruption in infants

Cardiometabolic diseases may serve as clinical markers for early-onset dementia

Hypertension and diabetes in midlife have been associated with increased risk of early-onset dementia, specifically the non-Alzheimer’s type, in a population-based case-control study.

Cardiometabolic diseases may serve as clinical markers for early-onset dementia

Regulatory approval delays for pembrolizumab & T-DXd in APAC highlight need for benefit-based prioritization

18 Aug 2026 bởi

A study conducted by the Asia-Pacific Oncology Drug Development Consortium finds substantial variability in regulatory approval delays of pembrolizumab and trastuzumab deruxtecan (T-DXd) across 10 Asia-Pacific (APAC) territories, and a lack of consistent prioritization of high-incidence tumours, high clinical benefit scores or curative treatment intent.

Regulatory approval delays for pembrolizumab & T-DXd in APAC highlight need for benefit-based prioritization

Gefurulimab for AChR-Ab–positive gMG succeeds in phase III trial

Gefurulimab, a novel bispecific nanobody that targets complement factor 5 (C5) delivers rapid and sustained clinical benefit in patients with anti–acetylcholine receptor antibody–positive (AChR-Ab+) generalized myasthenia gravis (gMG), as shown in the phase III PREVAIL trial.

Gefurulimab for AChR-Ab–positive gMG succeeds in phase III trial

Tim-3 blockade controls tumour growth in metabolic liver cancer

In patients with steatohepatitis-related hepatocellular carcinoma (HCC), Tim-3 plays a key role in regulating dendritic cell (DC) ferroptosis, with its expression predicting poor prognosis, suggests a study.

Tim-3 blockade controls tumour growth in metabolic liver cancer

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

Second-line treatment with adagrasib plus cetuximab demonstrates manageable safety but results in no statistically significant improvement in both progression-free (PFS) and overall survival (OS) in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) compared with chemotherapy, results of the KRYSTAL-10 trial have shown.

Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC

17 Aug 2026

Nicotinamide supplementation boosts human-milk vitamin B3 concentrations

Lactating women with no nicotinamide supplementation tend to have human-milk total vitamin B3 concentrations below the fifth percentile reference limit, a Tanzania study has found.

Nicotinamide supplementation boosts human-milk vitamin B3 concentrations

Kids with CAH exhibit distinct, age-dependent developmental deficits

In a cross-sectional study, children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency show distinct developmental challenges at different ages.

Kids with CAH exhibit distinct, age-dependent developmental deficits

Lower risk of asthma exacerbation with GLP-1 RA vs DPP-4i in patients with DM